找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Current Management of Melanoma; Ferdinando Cafiero,Franco De Cian Book 2021 Springer Nature Switzerland AG 2021 surgery treatment.sentinel

[復制鏈接]
樓主: fungus
41#
發(fā)表于 2025-3-28 17:50:21 | 只看該作者
Slips of Paper and Performance Artrocedure. Lymph node involvement is diagnosed in different ways, most frequently after sentinel lymph node biopsy (SLNB), but some patients may present clinical evident metastases at diagnosis or during the follow-up. In the case of positive SLNB, about 15–20% of patients have additional metastatic
42#
發(fā)表于 2025-3-28 21:50:28 | 只看該作者
https://doi.org/10.1007/978-3-319-45772-7mphocele, hematomas and lymphedema. Secondary lymphedema of the limbs is a debilitating and progressive condition that commonly occurs following melanoma treatment. The technique known as lymphatic microsurgical preventive healing approach (LYMPHA) is able to prevent secondary lymphedema following l
43#
發(fā)表于 2025-3-28 23:08:57 | 只看該作者
44#
發(fā)表于 2025-3-29 06:25:50 | 只看該作者
Zheng Liu,Shuting Guo,Tao Li,Wenyan Chen increase in surgical indications also for patients with metastatic melanoma. The surgical indications in this disease setting can be summarized as: collection of biological material; treatment of oligometastatic disease; treatment beyond progression; palliation surgery. In selected cases, surgical
45#
發(fā)表于 2025-3-29 10:59:38 | 只看該作者
Peizhong Yang,Lihua Zhou,Hongmei Chenith resected, high-risk melanoma. After a 20-year era of adjuvant interferon, checkpoint inhibitor immunotherapy and BRAF+MEK inhibitors revolutionized the management of melanoma in everyday clinical practice. In this review, we summarize the current state of the art of the adjuvant treatment of hig
46#
發(fā)表于 2025-3-29 13:09:00 | 只看該作者
47#
發(fā)表于 2025-3-29 16:06:48 | 只看該作者
48#
發(fā)表于 2025-3-29 22:43:09 | 只看該作者
49#
發(fā)表于 2025-3-30 02:03:36 | 只看該作者
Updates in Surgeryhttp://image.papertrans.cn/d/image/241238.jpg
50#
發(fā)表于 2025-3-30 06:09:33 | 只看該作者
 關于派博傳思  派博傳思旗下網站  友情鏈接
派博傳思介紹 公司地理位置 論文服務流程 影響因子官網 吾愛論文網 大講堂 北京大學 Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經驗總結 SCIENCEGARD IMPACTFACTOR 派博系數 清華大學 Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網安備110108008328) GMT+8, 2026-1-21 22:27
Copyright © 2001-2015 派博傳思   京公網安備110108008328 版權所有 All rights reserved
快速回復 返回頂部 返回列表
宕昌县| 拜泉县| 科技| 龙海市| 雅安市| 洞口县| 南昌县| 东明县| 新干县| 阿尔山市| 浦江县| 翁牛特旗| 长治市| 辽阳县| 宁河县| 安塞县| 成安县| 吉首市| 瑞金市| 共和县| 鹤峰县| 都兰县| 凤冈县| 阿城市| 剑河县| 南漳县| 玛沁县| 岢岚县| 海南省| 莫力| 庄河市| 茶陵县| 呈贡县| 东丰县| 昆山市| 黄冈市| 茂名市| 临夏市| 当雄县| 临西县| 遂昌县|